Latest Daily News

Latest News
June 5, 2017

Results from two separate trials suggest that lenalidomide can induce deeper and longer remission in patients with multiple myeloma when used as part of induction and maintenance therapy.

Read more
June 4, 2017

A planned interim analysis of the OPTIMAL˃60 trial found that a PET-based radiotherapy strategy to treat bulky disease is safe in elderly patients with diffuse large B-cell lymphoma.

Read more
June 4, 2017

Participants discussed 5- and 10-year follow-up data from two separate studies presented during the Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia Oral Abstract Session.

Read more

June 2, 2017

Treating multiple myeloma in older patients presents specific challenges and requires certain considerations. 

Read more
May 25, 2017

Dr. Mark Roschewski and Dr. Wyndham H. Wilson discuss circulating tumor DNA as a precision medicine tool for lymphoma.

Read more

May 25, 2017

A review of the 2016 changes to WHO Classification of Lymphoid Malignancies.

Read more
May 25, 2017

Joseph G. Jurcic, MD, and Mark L. Heaney, MD, PhD, answer a question posed by an attendee of a Best of ASCO® Meeting.

Read more
May 25, 2017

Brian J. Druker, MD, director of the Knight Cancer Institute at Oregon Health & Science University, will receive the 2017 Science of Oncology Award and Lecture.

Read more
June 6, 2016

A cytarabine and daunorubicin liposomal drug delivery platform outperformed 7+3 drug delivery in a phase III trial for secondary AML. 

Read more
June 6, 2017

Maintenance rituximab failed to prolong progression or improve survival compared with observation in an older group of patients with mantle cell lymphoma who underwent induction therapy with bendamustine/rituximab. 

Read more
June 6, 2016

PILLAR-2 failed to meet its primary endpoint of improved disease-free survival (DFS) with adjuvant everolimus in patients with poor-risk DLBCL. However, trends favoring everolimus for overall survival and lymphoma-specific survival and for DFS in selected subgroups were observed.

Read more
June 7, 2016

Addition of daratumumab to bortezomib and dexamethasone reduced the risk of disease progression or death by 61% in patients with relapsed/refractory multiple myeloma. Addition of the drug doubled rates of VGPR and CR, and it was associated with no cumulative toxicities.

Read more

June 7, 2016

CAR T-cell therapy could offer an exciting new treatment option for patients with relapsed or refractory ALL. However, many questions remain, including how to reduce toxicity associated with these therapies and select patient groups. Three clinical trials start to give answers.

Read more

June 7, 2016

Experts discussed specific approaches to immunotherapy, from the widely heralded PD-1 and PD-L1 blockade to more preliminary research into natural killer cell–mediated therapy.

Read more
June 7, 2016

Induction ABVD followed by consolidation with anti-CD3b brentuximab vedotin was promising for treatment of limited-stage Hodgkin lymphoma and may replace the use of radiation for these patients.

Read more
June 7, 2016

The oral abstract session covered the results of research on first-line therapy options for patients with newly diagnosed multiple myeloma. 

Read more

May 26, 2016

Cancer affects everyone, and the impact of the disease extends beyond the patient to those close to them. Himself a cancer survivor, Chicago Cubs first baseman Anthony Rizzo founded the Anthony Rizzo Family Foundation to raise money to support families fighting cancer and for cancer research.

Read more

May 26, 2016

Significant gaps exist in end-of-life outcomes in hematologic oncology compared to solid-tumor oncology. Dr. David Hui and colleagues discuss possible reasons why, and the steps that can be taken to bridge these gaps.

Read more

May 26, 2016

An Education Session examining high-and low-risk cases of Hodgkin lymphoma in adolescents and young adults will use a case-based format to focus on the differences between how patients are approached, depending on whether they are being treated by adult oncologists or pediatric oncologists. 

Read more

May 26, 2016

Dr. Saad Z. Usmani answers the following question posed by an attendee during a 2015 Best of ASCO® Meeting: What is the recommended method of risk stratification for multiple myeloma?

Read more